Followers | 834 |
Posts | 119875 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
Wednesday, April 25, 2018 4:38:21 PM
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent SNDX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 01:26:27 PM
- Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress • PR Newswire (US) • 06/14/2024 11:00:00 AM
- Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger • GlobeNewswire Inc. • 06/10/2024 11:30:00 AM
- Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 06/03/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:04:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:03:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:11:37 PM
- Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors • PR Newswire (US) • 05/15/2024 08:05:00 PM
- Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference • PR Newswire (US) • 05/09/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update • PR Newswire (US) • 05/08/2024 11:06:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 11:04:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:03:25 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 05/03/2024 08:05:00 PM
- Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 • PR Newswire (US) • 05/01/2024 11:00:00 AM
- Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum • PR Newswire (US) • 04/10/2024 08:05:00 PM
- Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session • PR Newswire (US) • 04/08/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/05/2024 08:05:00 PM
- Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia • PR Newswire (US) • 03/28/2024 11:00:00 AM
- Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia • PR Newswire (US) • 03/26/2024 08:05:00 PM
- Syndax Announces Appointment of Steven Closter as Chief Commercial Officer • PR Newswire (US) • 03/18/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/01/2024 09:05:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/27/2024 10:28:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 10:21:34 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM